单体核型对接受5-阿扎胞苷治疗的高危骨髓增生异常综合征患者的预后价值:希腊骨髓增生异常综合征研究组的回顾性分析
该回顾性分析纳入405例接受5-阿扎胞苷(5-AZA)治疗的高危骨髓增生异常综合征(MDS)患者,66例(16.3%)存在单体核型(MK)。MK+患者总生存期(中位12个月 vs 18个月,P<.001)及至急性髓系白血病转化时间(中位17个月 vs 23个月,P=.025)均劣于MK-患者,且MK为总生存期的独立不良预后因素(P=.002)。
要点
- 高危MDS接受5-AZA治疗者中MK发生率为16.3%,且多合并复杂核型。
- MK+患者中位总生存期12个月,MK-患者18个月(P<.001)。
- IPSS-R高危/极高危亚组中,MK+患者中位总生存期仍劣于MK-患者(12个月 vs 17个月,P=.002)。
核心结论
- 在高危MDS接受5-AZA治疗的患者中,MK与总生存期缩短相关。
- 在IPSS-R高危或极高危评分的MDS中,MK可进一步区分预后更差的患者。
研究设计与样本
- 希腊MDS研究组开展的回顾性分析,纳入405例接受5-AZA治疗的高危MDS患者。
主要发现
- 405例中66例(16.3%)存在MK,多数合并复杂核型。
- MK与复杂核型、IPSS-R细胞遗传学风险及IPSS(P=.029)、IPSS-R(P<.001)、WPSS(P<.001)高危疾病分类系统强相关。
- MK+与MK-患者总缓解率无差异(46.6% vs 46.2%)。
- 中位随访28个月时,全队列中位缓解持续时间11个月,MK+患者9.5个月,MK-患者11个月(P=.024)。
- MK+患者估计中位至急性髓系白血病转化时间17个月,MK-患者23个月(P=.025);MK+患者估计中位总生存期12个月,MK-患者18个月(P<.001)。
关键数值与推荐
- 多因素Cox回归分析显示,体能状态(P<.001)、IPSS-R(P<.001)和MK(P=.002)与总生存期独立相关。
- 在IPSS-R高危和极高危亚组中,MK-患者总生存率优于MK+患者(估计中位总生存期17个月 vs 12个月,P=.002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this study, we investigated the incidence and prognostic impact of monosomal karyotype (MK) in 405 higher-risk Myelodysplastic Syndromes (MDS) patients treated with 5-AZA. The MK was present in 66 out of 405 (16.3%) patients, most of whom had complex karyotype (CK). MK was strongly associated with CK and the cytogenetic risk defined according to IPSS-R, as well as with high-risk disease, according to IPSS (P = .029), IPSS-R (P < .001), and WPSS (P < .001) classification systems. The overall response rate (ORR) was not different between MK+ and MK- patients (46.6% vs. 46.2%). At 28 months median follow-up, the median duration of response was 11 months in the entire cohort, 9.5 months in MK+ patients and 11 months in MK-patients (P = .024). The estimated median time to transformation to acute myeloid leukemia for MK+ patients was 17 months vs. 23 months for MK- patients (P = .025). The estimated median OS for MK+ patients was 12 months vs. 18 months for MK- patients (P < .001). Multivariate Cox regression analysis revealed that performance status (P < .001), IPSS-R (P < .001), and MK (P = .002) were independently associated with overall survival (OS). In a subgroup consisting of high and very-high risk patients according to IPSS-R, MK- patients showed better OS rates compared to MK+ patients (estimated median OS: 17 months vs. 12 months, P = .002). In conclusion, we found that MK is associated with reduced OS in patients with higher-risk MDS treated with 5-AZA. Furthermore, we showed that in MDS with high or very-high IPSS-R risk score, MK can further distinguish patients with worse outcome.
引用
- Papageorgiou SG, Vasilatou D, Kontos CK, et al. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. Am J Hematol. 2018. PMID: 29659040. doi:10.1002/ajh.25111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。